ArticleNew microbes and new infections2026
Resilience and residuals beyond containment - The hidden burden of Bundibugyo Ebola virus survivorship sixteen years on: A cross-sectional observational study.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bundibugyo virus disease evidence map: a rapid research needs appraisal.EClinicalMedicine · 2026Article
- Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus.Viruses · 2026Review
- Mapping the global evidence base of bundibugyo ebolavirus disease: a systematic scoping review of research gaps and preparedness priorities.BMC infectious diseases · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term effects of Ebola disease (EBOD) are well documented for Ebolavirus (EBOV), but limited data exist for Bundibugyo virus disease (BVD) caused by Bundibugyo Ebola virus (BDBV), a genetically distinct strain. Methods: We conducted a cross-sectional observational study involving 40 laboratory-confirmed BVD survivors and 23 age- and sex-matched unexposed community controls to evaluate the long-term clinical, biochemical, immunological, and psychosocial sequelae associated with BDBV infection. Participants underwent comprehensive clinical evaluations, laboratory testing, and standardised mental health assessments. Statistical comparisons used rank-sum, chi-squared, and correlation analyses. Findings: Survivors exhibited persistent multisystem symptoms, with neurological and musculoskeletal complaints most frequent, headaches (35 %) and visual disturbances (22.5 %). Laboratory findings showed elevated basophils (40 %) and urinary ketones (5 %), indicating possible chronic inflammation and metabolic shifts. Respiratory rates were significantly reduced in survivors (p < 0.001), while other vital signs and biochemical markers were largely within normal ranges. Despite high resilience, 70 % with normal anxiety scores and 62.5 % with normal depression scores, 57.5 % reported persistent stigma. Survivors also exhibited unique physiological correlations, suggestive of post-infectious homeostatic changes. Conclusion: BVD survivors experience long-term multisystem sequelae and physiological remodeling. These findings support the need for virus-specific post-BVD care and sustained follow-up to inform survivor health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.